Aviva PLC Grows Stake in Neurocrine Biosciences, Inc. $NBIX

Aviva PLC lifted its holdings in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 1,059.3% during the 2nd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 61,746 shares of the company’s stock after acquiring an additional 56,420 shares during the period. Aviva PLC owned 0.06% of Neurocrine Biosciences worth $7,761,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Los Angeles Capital Management LLC raised its holdings in Neurocrine Biosciences by 19,454.9% during the second quarter. Los Angeles Capital Management LLC now owns 744,650 shares of the company’s stock worth $93,595,000 after purchasing an additional 740,842 shares in the last quarter. Prospera Financial Services Inc grew its position in shares of Neurocrine Biosciences by 43.3% in the 2nd quarter. Prospera Financial Services Inc now owns 3,835 shares of the company’s stock valued at $482,000 after buying an additional 1,158 shares during the last quarter. True Wealth Design LLC raised its stake in Neurocrine Biosciences by 1,215.4% during the 2nd quarter. True Wealth Design LLC now owns 342 shares of the company’s stock worth $43,000 after acquiring an additional 316 shares in the last quarter. Savant Capital LLC lifted its position in Neurocrine Biosciences by 128.7% in the second quarter. Savant Capital LLC now owns 23,242 shares of the company’s stock valued at $2,921,000 after acquiring an additional 13,079 shares during the last quarter. Finally, Cetera Trust Company N.A boosted its stake in Neurocrine Biosciences by 11.0% in the second quarter. Cetera Trust Company N.A now owns 2,430 shares of the company’s stock valued at $305,000 after acquiring an additional 240 shares in the last quarter. 92.59% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, CEO Kyle Gano sold 300 shares of the stock in a transaction dated Tuesday, November 4th. The shares were sold at an average price of $141.97, for a total value of $42,591.00. Following the completion of the transaction, the chief executive officer owned 140,407 shares in the company, valued at $19,933,581.79. This trade represents a 0.21% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director William H. Rastetter sold 18,000 shares of the firm’s stock in a transaction dated Wednesday, November 5th. The shares were sold at an average price of $151.82, for a total transaction of $2,732,760.00. Following the completion of the sale, the director owned 40,360 shares of the company’s stock, valued at $6,127,455.20. This trade represents a 30.84% decrease in their position. The disclosure for this sale is available in the SEC filing. 4.80% of the stock is currently owned by company insiders.

Neurocrine Biosciences Trading Down 0.3%

Shares of NBIX opened at $146.85 on Thursday. The stock’s 50 day moving average is $142.55 and its two-hundred day moving average is $132.33. Neurocrine Biosciences, Inc. has a twelve month low of $84.23 and a twelve month high of $157.67. The firm has a market capitalization of $14.64 billion, a PE ratio of 35.13, a P/E/G ratio of 0.94 and a beta of 0.22.

Neurocrine Biosciences (NASDAQ:NBIX) last issued its earnings results on Tuesday, October 28th. The company reported $2.04 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.58 by $0.46. Neurocrine Biosciences had a return on equity of 15.82% and a net margin of 15.95%.The business had revenue of $794.90 million during the quarter, compared to the consensus estimate of $746.61 million. During the same period in the prior year, the business posted $1.81 EPS. The company’s revenue for the quarter was up 27.8% on a year-over-year basis. On average, sell-side analysts predict that Neurocrine Biosciences, Inc. will post 4.28 EPS for the current year.

Analyst Ratings Changes

Several equities analysts have issued reports on the company. Zacks Research raised Neurocrine Biosciences from a “hold” rating to a “strong-buy” rating in a report on Wednesday, October 15th. Truist Financial restated a “buy” rating and set a $172.00 price target (up previously from $165.00) on shares of Neurocrine Biosciences in a research note on Thursday, October 30th. Wedbush reiterated an “outperform” rating on shares of Neurocrine Biosciences in a research note on Monday, September 22nd. Citigroup increased their price objective on Neurocrine Biosciences from $175.00 to $203.00 and gave the company a “buy” rating in a report on Wednesday, October 29th. Finally, Stifel Nicolaus lifted their target price on shares of Neurocrine Biosciences from $174.00 to $183.00 and gave the company a “buy” rating in a report on Wednesday, October 29th. One investment analyst has rated the stock with a Strong Buy rating, eighteen have given a Buy rating and three have given a Hold rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $170.53.

Neurocrine Biosciences Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.